The following is a summary of the Lisata Therapeutics, Inc. (LSTA) Q1 2024 Earnings Call Transcript:

Financial Performance:

• Lisata reported Q1 2024 operating expenses of $6.6 million, a decrease of 3.6% compared to 2023.

• Research and Development expenses saw a negligible increase of $62,000, or 2%.

• General and Administrative expenses fell down by 8.3% due to reduced staffing costs and legal consulting fees.

• Lisata recorded a net loss of $5.4 million for Q1 2024, down by 13% from 2023.

• Lisata held cash equivalents of $43.3 million as of March 31 believed to fund operations till early 2026.

Business Progress:

• Lisata's lead product certepetide is undergoing development for treating solid tumor cancers.

• The company is focused on key milestones from their ongoing clinical trials.

• They plan to maintain certepetide's conditional approval through required Phase 3 studies.

• Its development strategy involves a rapid certepetide registration for treating metastatic pancreatic ductal adenocarcinoma.

• Lisata terminated its trials on head and neck and esophageal cohorts, now focusing on the cholangiocarcinoma arm of the BOLSTER trial.

More details: Lisata Therapeutics IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.